System and method for modulation of deep brain circuit
By using ultrasound phased array equipment and RTT method, the attenuation of the skull and scalp can be directly measured and compensated, achieving high spatiotemporal resolution neuromodulation. This solves the complexity and safety issues of deep brain target therapy and provides a non-invasive, high-precision neuromodulation solution.
Patent Information
- Application Number
- CN202380021152.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-04
- Filing Date
- 2023-01-04
- Publication Date
- 2024-11-15
AI Technical Summary
Existing neuromodulation methods are limited by the uncertainty of neural circuits at deep brain targets and the unpredictable attenuation of ultrasound in the human skull, leading to treatment complications and safety issues.
Using an ultrasound phased array device, combined with the RTT method, the attenuation of the skull and scalp is directly measured and compensated. High spatiotemporal resolution ultrasound delivery is achieved through a head-mounted transducer array device, correcting attenuation and phase shift in the ultrasound path to ensure that ultrasound energy accurately reaches the designated brain target.
It achieves non-invasive, high-precision neuromodulation, safely and effectively targeting deep brain targets, reducing side effects, and improving the personalization and predictability of treatment.
Smart Images

Figure CN118973502A_ABST
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a non-provisional application of U.S. Provisional Patent Application No. 63 / 296,252 filed on January 4, 2022, and claims the benefit of the same, the contents of which are incorporated herein by reference. Technical Field
[0002] The present disclosure relates to systems and methods for applying and modulating ultrasound to a designated target in the human brain. Background Art
[0003] About one-third of patients with psychiatric and neurological diseases are refractory. Neuromodulation has the potential to provide targeted resetting for faulty circuits. However, current neuromodulation methods are limited by two major obstacles. First, the exact neural circuits involved in psychiatric and neurological disorders are poorly understood and appear to vary from individual to individual. This uncertainty limits the robust application of deep brain stimulation to such patients. Second, common conditions such as depression, anxiety, and pain-related disorders involve neural networks located deep in the brain, including limbs, basal ganglia, and brainstem networks. These deep brain sources complicate treatment using current noninvasive neuromodulation methods. For example, electroconvulsive therapy uses large currents that cause whole-brain epileptic seizures to modulate deep brain structures. This widespread activation often leads to cognitive side effects such as memory loss. Transcranial magnetic stimulation may modulate deep brain networks via connections to stimulated cortical areas, but this indirect involvement contributes to variable responses.
[0004] Ultrasound-based neuromodulation has the potential to modulate deep brain targets selectively and with high spatiotemporal resolution.
[0005] Compared to studies in small animal models, ultrasound-based neuromodulation has shown limited effectiveness when administered through the human head. It has been determined that the intensity of neuromodulation ultrasound is attenuated by the human skull alone by a factor of 4.5-64, depending on the skull fragment and the individual. This large variability in the attenuation factor makes it impossible to provide a confident estimate of the delivered intensity. Therefore, to mitigate the risk of injury to the brain, studies in humans are forced to take a "worst-case scenario" approach, assuming minimal attenuation. This conservative approach—necessary for safety—has static effectiveness.
[0006] Furthermore, effective and safe treatment of brain disorders requires the selective delivery of ultrasound to restricted brain regions or individual nuclei. Current single element transducers for neuromodulation only provide cigar-shaped beams that typically extend over a few centimeters, providing only limited spatial specificity. Furthermore, these solutions do not have the precision and flexibility of phased arrays, which complicates selective delivery to multiple targets, targeted fine-tuning, and system application. The lack of precision and flexibility limits the use of existing solutions to patients suffering from deep brain circuit disorders.
[0007] Therefore, a device that compensates for the human skull and delivers ultrasound into designated deep brain targets with high spatiotemporal resolution is desired. Summary of the invention
[0008] Transcranial focused ultrasound provides a non-invasive and reversible method for precise and personalized manipulation of brain circuits, which has the potential to transform the understanding of brain function and the treatment of brain dysfunction. Ultrasound can be focused through the intact skull and scalp into specific deep brain regions that can span several millimeters in diameter.
[0009] Because ultrasound reaches the target in microseconds, ultrasound arrays have the ability to stimulate multiple sites simultaneously or in fine time sequences. The precise focusing of the commands opens up unique new possibilities to systematically modulate faulty circuits in each individual. Furthermore, transducer arrays are able to programmatically focus ultrasound into designated brain targets without moving the device or subject.
[0010] However, as described above, the effectiveness and safety of these approaches are limited by the human head, which strongly and unpredictably attenuates and distorts ultrasound. This hindrance is caused by the strong and unpredictable attenuation of ultrasound by the head and the limited targeting accuracy of existing devices. To address these issues, ultrasound phased array devices have been developed that compensate for ultrasound distortion of the head and deliver ultrasound to designated target(s) with high spatiotemporal resolution. The devices are able to verify target engagement inside the MRI and can be reused outside the MRI.
[0011] To address the ultrasound attenuation problem, a "Relative Through-Transmit" (RTT) method has been developed that directly measures and compensates for the attenuation and distortion of a given skull and scalp. RTT has been implemented in hardware and demonstrated that it accurately restores the operator's intended intensity inside an ex vivo human skull. Furthermore, this functionality enables efficient and intensity-dependent transcranial modulation of nerves and effective delivery of defined doses of propofol inside the skull. Thus, the present disclosure provides a tool to non-invasively and effectively modulate specific neural circuits deep within the human brain to provide therapeutic options to the millions of people who are resistant to current treatments.
[0012] Devices as disclosed herein provide diagnostic information to guide deep brain stimulation implants, advance the understanding of human brain function, and offer a new means to induce durable circuit resetting in refractory patients.
[0013] In some embodiments, the systems and methods described herein provide high precision ultrasound treatments that can be used, for example, in a mental health or neurology clinic. In some embodiments, the system provides a mechanism for controlling the ultrasound dose delivered through the head to produce predictable effects in target areas. In some embodiments, the system enables multi-focal manipulations that predictably modulate specific brain regions based on the specific needs of the patient.
[0014] In some embodiments, the system includes a head-mounted transducer array device including 64 to 1,024 transducer elements inserted into a 3D printed frame having a geometry optimized for a specific multifocal operation in a specific individual. Due to the minimal attenuation of ultrasound by brain tissue, it is possible to deliver ultrasound to deep brain targets. However, the head and skull are particularly de-phased and attenuate ultrasound waves. Therefore, in some embodiments, the systems and methods described herein use ultrasound itself to correct (also referred to as "compensate") the ultrasound aberrations of the head. In this way, the head aberrations are measured directly and accurately, and no additional head scans such as CT or MRI are required. Specifically, the method performs ultrasound RTT measurements through each corresponding segment of a given head. This provides phase and amplitude values for correcting the aberrations of each segment of a specific head. The amplitude of the corresponding ultrasound transducer is scaled and phase-shifted to deliver undistorted, deterministic intensity to the treatment target. In some embodiments, specific features of the through-transmission waveform can be optimized to maximize the accuracy of the detection of the ultrasound energy delivered through the head, and therefore maximize the accuracy of the head correction.
[0015] In some embodiments, the systems and methods described herein are configured and applied to treat anxiety and depression-related disorders, including post-traumatic stress disorder. These disorders involve abnormal connectivity of two deep brain regions, the subgenual cingulate gyrus and the amygdala, with adjacent circuits. Tens of seconds of low-intensity ultrasound directed to the cingulate gyrus and the amygdala can induce lasting changes in the associated circuits. In some embodiments, the systems and methods described herein are configured to target those regions (e.g., using human cadavers as models).
[0016] In some embodiments, the systems and methods described herein are configured and adapted to treat thalamic nuclei, such as those involved in pain. These conditions involve abnormal connectivity of the thalamic nuclei, insular cortex, cingulate cortex, nucleus accumbens, and ventral tegmental area. Tens of seconds of ultrasound targeting these circuits modulate pain thresholds. In some embodiments, the systems and methods described herein are configured to target those areas (e.g., using human cadavers as models).
[0017] In some embodiments, targeting of these areas can be verified using fMRI BOLD (blood oxygen level dependent imaging), MRI thermometry, or MRI acoustic radiation force imaging. These imaging sequences visualize the areas affected by ultrasound and can therefore increase the reproducibility of ultrasound therapy and minimize potential off-target effects.
[0018] In some embodiments, MRI can be used to establish the subject-specific anatomy of the head and brain.
[0019] In one embodiment, the present disclosure provides a method for applying transcranial ultrasound to a target brain location. At least one transmitting ultrasound transducer is driven to generate ultrasound waves so as to achieve the expected ultrasound energy at the target location in a free field volume corresponding to the target brain location. The ultrasound waves leaving the free field volume are measured by at least one receiving ultrasound transducer positioned at a fixed distance and orientation relative to at least one transmitting ultrasound transducer on the opposite side of the free field volume. The head is then positioned between the transmitting and receiving ultrasound transducers, and the transmitting ultrasound transducer is driven again to generate the same ultrasound waves entering the head, and the receiving ultrasound transducer measures the ultrasound waves leaving the head, which are changed at least in part due to the presence of the head in the ultrasound path between the transmitting ultrasound transducer and the receiving ultrasound transducer. One or more adjusted ultrasound waveforms are then determined based on the difference between the ultrasound waves measured through the free field volume and the changed ultrasound waves measured through the head, wherein the adjusted ultrasound waves compensate for the attenuation and phase shift caused by obstacles in the ultrasound path, so as to deliver actual ultrasound stimulation energy at the target brain location to approach the expected ultrasound stimulation energy at the target location. The transmitting ultrasonic transducer is then driven to generate the modulated ultrasonic waves into the head.
[0020] In another embodiment, the present disclosure provides an ultrasound-based neurostimulation system including a head-mounted device and a controller. The head-mounted device includes at least one ultrasound transducer array including ultrasound transducers positioned on opposite sides of the head. The controller is configured to determine a set of ultrasound waves to be emitted by the ultrasound transducers to achieve the desired ultrasound stimulation energy at a target location within a volume. The controller drives a first set of ultrasound transducers and uses a second set of ultrasound transducers on the opposite side of the volume to capture the propagated ultrasound waves. This is performed twice: once in a free field when the head-mounted device is not applied to the head, and once when the head-mounted device is applied to the head. The controller compares the free field measurement and the through transmission measurement to determine the attenuation and phase shift in the ultrasound waves caused at least in part by the presence of the skull in the ultrasound path. The controller determines an adjusted ultrasound set that compensates for the determined attenuation and the determined phase shift so as to achieve the desired ultrasound stimulation energy at the target location within the volume when the head-mounted device is applied to the head. When the head mounted device is applied to the head, the controller drives the transducer group according to the determined adjusted ultrasonic wave group.
[0021] In yet another embodiment, the present disclosure provides a method for applying a deterministic ultrasound dose to a target brain location by driving an ultrasound transducer array to perform through-transmission ultrasound measurements with and without a subject's head. Based on the through-transmission ultrasound measurements, the attenuation and phase shift of ultrasound due to the head is determined compared to the absence of the head. Corrected amplitude and phase values are determined for each ultrasound transducer, and then the ultrasound transducer array is driven based on the adjusted amplitude and phase values to achieve the desired ultrasound stimulation energy at the target brain location within the skull.
[0022] Other aspects of the invention will become apparent by consideration of the detailed description and accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0024] Figure 1 is a block diagram of a system for applying ultrasound stimulation according to one embodiment.
[0025] Figure 2 yes Figure 1 A perspective view of an example of a head-mounted transducer array device of the system.
[0026] Figure 3 yes Figure 1 A perspective view of another example of a head-mounted transducer array device of a system.
[0027] Figure 4 Yes Wear Figure 3 A series of MRI images captured of a subject wearing a head-mounted transducer array device and a subject not wearing a head-mounted transducer array device.
[0028] Figure 5A Ultrasonic waves are emitted through a free field volume. Figure 3 A perspective view of the transducer array of a head-mounted transducer array device.
[0029] Figure 5B Ultrasound waves are sent through the subject's head. Figure 3 A perspective view of the transducer array of a head-mounted transducer array device.
[0030] Figure 5C It is a superposition of ultrasound beams from a transducer array on an MRI image.
[0031] Figure 6 is a graph of the intensity attenuation of various segments of the skull.
[0032] Figure 7 It is due to Figure 5C Graph showing the expected intensity and actual intensity of the ultrasonic wave emitted at the target point due to the attenuation at the ultrasonic target point shown in .
[0033] Figure 8 The method of measuring ultrasound aberration through the skull according to an embodiment of the present disclosure is schematically illustrated.
[0034] Fig. 9 is a flow chart of a method for applying ultrasound stimulation to a target location in a subject's brain after adjusting the stimulation waves to compensate for attenuation and phase changes caused by the subject's skull.
[0035] Fig.10 It shows that according to Fig. 9 A series of graphs showing the measured intensity of an ultrasound beam transmitted in the absence of a skull, the measured intensity of the same transmitted ultrasound beam attenuated by a human skull (n=8), and the measured intensity of the ultrasound beam after passing through the skull after correction for the method. The bar graph shows Fig. 9 How to restore the expected strength at deep brain targets.
[0036] Fig.11 It is shown Fig. 9 Graph of the method's correction relative to the accuracy of stimulation of the subject's nerve with the thumb positioned inside the skull.
[0037] Fig.12 It shows that Fig.11 Graphs of the response data for the subjects at the highest ultrasound pressures shown in FIG. 1 for the subjects without skull, with skull, with Fig. 9 The method compensates for the presence of the skull and targets the stimulation at 10 mm off-target.
[0038] Fig.13 is a graph showing the expected stimulus, the actual stimulus (after attenuation by the skull), and the Fig. 9 Figure 3. Graph of the measured peak pressure of the method-compensated stimulus.
[0039] Fig.14 It shows that according to Fig. 9 A graph of the change in focal volume of the area stimulated by the applied ultrasound due to skull distortion and ultrasound compensation.
[0040] Fig.15 is applied to the patient Figure 1 A perspective view of an example of a head-mounted transducer array device of the system.
[0041] Fig.16 A head mounted transducer array device is shown producing a spatially focused intensity field through the skull. Intensity field at the focus of the device measured through an ex vivo human skull.
[0042] Fig.17A and Fig. 17B The intensity field produced by the transducer array overlaid on the subject's brain anatomy is shown.
[0043] Fig. 17C and 17D The fMRI BOLD response resulting from stimulation at the targeted region is shown.
[0044] Fig.17E The fMRI BOLD response at the target site is shown to be time locked to stimulus onset.
[0045] Fig.17F and 17G Shown is an active sham stimulation with the same stimulation parameters, but the array focused outside the subject's head (plane wave) elicited no BOLD response at the target site.
[0046] Fig.18 It is shown in graphical form that stimulation improves mood states in depressed patients. Self-reported mood scores after each stimulation show reduced anxiety and depression and increased feelings of pleasure. Sham stimulation did not cause any changes in the mood ratings of the subjects.
[0047] Fig.19 An example correction method is shown. This method uses through-transmission measurements from all element pairs to solve for the attenuation and acceleration encountered in front of each element, and then adjusts the stimulation parameters to correct for these distortions.
[0048] Fig. 20 is a graph showing the average attenuation correction across sessions. Variability was observed between sessions due to the quality of acoustic coupling between the transducer and the subject's head. Elements that were not connected properly (with an average pressure transmission < 12%) were turned off.
[0049] Fig.21 are graphs indicating that mechanical registration provides reproducible targeting across time periods. a. Deviation between the location of the ultrasound focus and the brain target across five human subjects. b. Targeting error depicted by spatial dimension.
[0050] Fig. 22 are graphs indicating that mechanical registration provides reproducible targeting across time periods. a. Deviation between the location of the ultrasound focus and the brain target across five human subjects. b. Targeting error depicted by spatial dimension.
[0051] Fig.23 An image where the blue area indicates the electronic steering range available for the head mounted transducer array device. The focus of the device through the ex vivo human skull is superimposed onto the MRI image for zooming. The focus can be beamformed to any position within this region in microseconds without physical movement of the device.
[0052] Fig.24 Shown is the ultrasound attenuation of the human skull.
[0053] Fig.25 It is shown that RTT accurately compensates for each skull and restores the expected intensity at the target. Ultrasound fields obtained inside ex vivo human skulls for assumed ideal correction (grey), no correction (red), and RTT (green) (n=8). The top bar shows the spatial peak intensity of the field in each case. The bottom graph provides the corresponding spatial distribution of the ultrasound field relative to the target.
[0054] Fig.26 Shown is the effect of RTT applied through a human head. Average through transmission attenuation values for all elements across 5 human subjects and 8 ex vivo human skulls. No hair shaving is required to obtain a robust through transmission signal.
[0055] Fig. 27 RTT performance as a function of range of motion is shown. Targets are included that encompass the full steering range of the array: 10mm axial, 20mm axial, 10mm lateral, 20mm lateral, and 15mm elevational from the center target. The axial direction refers to the line connecting the centers of the two transducers.
[0056] Fig.28Shown that phase correction is insufficient to account for skull attenuation. Spatial peak intensity at the central target using the phase correction component (a), the amplitude component (b), and the two components of RTT (c).
[0057] Fig.29 The RTT is shown to be robust on different hardware. (a) Array geometry of the head-mounted transducer array device. The associated correction values are Fig.25 The correction performs worse in Subject 8 (purple marker), who has the thickest skull with bone growth and possible bone hyperplasia. (b) Array geometry of a head-mounted transducer array device with a larger aperture and associated correction data.
[0058] Fig.30 RTT is shown to achieve effective ultrasound stimulation through the skull. (a) RTT achieves effective modulation of peripheral nerves through the skull. The array targeted nerves in the thumbs of 11 participants. The thumb was fixed in a central target inside the ex vivo skull. The array delivered 300ms of stimulation to the target at a frequency of 650kHz and a pressure amplitude of 1.8MPa. Data were collected with ideal correction (black), without any correction (red), and after applying RTT (green). The sham condition delivered stimulation 10mm below the finger (yellow). Individual conditions were randomly presented every 8-12 seconds for a total of 10 repetitions. Subjects reported any noxious response, which indicates that the nerves and nerve endings were stimulated. The response frequency represents the proportion of trials in which the subject reported a noxious response. (b) Dose-response relationship of the stimulation. There was significant modulation of ultrasound pressure, but there was no significant difference in the response after ideal (black) and RTT (green) correction (see text for details). LOW, MEDIUM, and HIGH markers correspond to expected peak pressures of 1.3, 1.55, and 1.8 MPa measured in free field. Error bars represent sem.
[0059] Fig.31 Nerve stimulation in each subject is shown. Ideal (black) and RTT (green) corrected mean response rates for each individual subject. When no RTT was applied, there was no significant effect of ultrasound nerve stimulation (red; t11=1.00, p=0.34, one sample t test).
[0060] Fig.32 RTT is shown to achieve effective and dose-dependent local drug release. (a) RTT achieves effective drug release from a nanoparticle carrier. A safe, biocompatible nanoparticle carrier encapsulates the neuromodulatory drug propofol. The nanoparticles release their drug load when subjected to low to moderate intensity ultrasound. Fig.30Similarly, a vial with nanoparticles is positioned in the center of an ex vivo skull. Ultrasound delivered through the skull impinges on the nanoparticles in pulses of 100 milliseconds delivered every 1 second for 60 seconds, at a frequency of 650 kHz and a pressure amplitude of 1.8 MPa. Data were collected under an assumed ideal correction for the skull (black), without any correction (red), and after applying RTT (green). A sham condition delivered the stimulus 10 mm below the vial (yellow). A second sham condition placed the vial at the target but did not deliver ultrasound (purple). The dotted line represents the baseline when no ultrasound is applied. The baseline can be non-zero due to free (unencapsulated) drug or due to partial leakage of the nanoparticles. Similar to Fig.30 , individual conditions were randomly interleaved. Bars include n = 10 different samples, except for the no-sonication condition, which used n = 6. Error bars represent sem. (b) Dose-response relationship. LOW, MEDIUM, and HIGH markers correspond to expected peak pressures of 1.2, 1.5, and 1.8 MPa measured in free field. All data points include n = 10 different samples. Error bars represent sem.
[0061] Fig.33 Shows that compensation of ultrasound attenuation by the head is critical for effective neuromodulation. The figure shows the statistical significance of fMRI BOLD signal modulation by ultrasound at deep brain targets when correction is applied (left) and without correction (right). DETAILED DESCRIPTION
[0062] Before any embodiments of the invention are explained in detail, it should be understood that the invention is not limited in its application to the details of construction and arrangement of components set forth in the following description or illustrated in the following drawings. The invention is capable of other embodiments and can be practiced or carried out in various ways.
[0063] The systems and methods presented in the following embodiments provide a non-invasive ultrasound-based neuromodulation device that can be used, for example, for the treatment and / or diagnosis of neurological and psychiatric disorders. The device is worn on the head and coupled at several points around the skull. This positioning allows the device to deliver ultrasound waves from the transducer to designated deep brain targets. The device is controlled by an operator who can select a specific brain area as a target for the ultrasound waves. A treatment plan for the patient can be generated to automatically control which transducer(s) delivers (one or more) ultrasound waves to (one or more) deep brain targets. The device performs a compensation routine to correct for ultrasound obstacles, which typically include the skull, hair, and ultrasound coupling, and emits waves with amplitude and timing from an array of individual transducers so that the ultrasound reaches the defined target with the expected intensity.
[0064] In some embodiments, the system is configured to correct for ultrasound aberrations of the skull by using the ultrasound itself and the same frequency as that used for diagnosis and treatment. As opposed to estimation, the device measures the skull directly, which allows for more accurate, safer, and more effective treatments. The device obtains this measurement by measuring the actual attenuation and dephasing of the ultrasound via a relative through-transmission measurement through the skull. The system then takes these measured attenuation and phase values and compensates for them by adjusting the amplitude and phase of each of its elements. Measurement of ultrasound skull aberrations using the ultrasound itself provides accurate compensation for delivering ultrasound intensity into designated brain targets, sharpens the ultrasound focus, and therefore leads to more precise, safer, and more effective treatments.
[0065] In some embodiments, the head-mounted device includes 256 transducer elements attached to a custom, patient-specific 3D printed frame. This modular design allows for targeting of specific brain regions in each patient.
[0066] Figure 1 An example of an ultrasound-based neurostimulation system 100 for deep brain diagnostics is shown. The system 100 includes a controller 101 that includes an electronic processor 103 and a non-transitory computer-readable memory 105. The electronic processor 103 is communicatively coupled to the memory 105 and is configured to store data to the memory 105 and access stored data from the memory 105. The memory 105 also stores computer-executable instructions that, when executed by the electronic processor 103, provide the functionality of the controller 101, including, for example, the functionality described herein. Although Figure 1 The example of only one memory 105 is shown in other embodiments, but the system can utilize multiple different memory modules, including, for example, local memory, external storage devices, and / or remote or cloud-based memory systems. Similarly, in different embodiments, the system 100 can utilize one or more electronic processors implemented in one or more different computing devices. In some embodiments, the controller 101 can be implemented as a dedicated controller device, while in other embodiments, the controller 101 can be provided as a desktop computer, a laptop computer, or a tablet computer. In other embodiments, the controller 101 may include multiple different control devices, including, for example, an electronic controller incorporated into or directly coupled to the head-mounted device described below and a computer communicatively coupled to the electronic controller. Therefore, unless otherwise specified, the controller 101 may include one or more computing devices and / or control circuits, one or more electronic processors, and one or more memories.
[0067] like Figure 1As shown in the example of , the controller 101 is communicatively coupled to a plurality of ultrasonic transducers 107 including ultrasonic transducers 107.1, 107.2, and 107.n. In the specific example described herein, the plurality of ultrasonic transducers 107 includes 256 ultrasonic transducers arranged in one or more arrays that are incorporated into the head mounted device.
[0068] As described in further detail below, the controller 101 is configured to selectively and controllably cause the ultrasonic transducers 107 in the (multiple) arrays to emit ultrasonic waves and define / control the parameters of the emitted ultrasonic waves. The controller 101 is also configured to receive output data from other ultrasonic transducers in the array. In this way, the ultrasonic transducers 107 are operated by the controller 101 to emit and receive ultrasonic waves. In some embodiments, the controller 101 is configured to communicate electronically directly with each ultrasonic transducer 107, while in other embodiments, the controller 101 is indirectly coupled to the plurality of ultrasonic transducers 107 through a data acquisition and / or signal routing device (not shown), which is incorporated into the controller 101 or provided as a separate additional device.
[0069] Figure 2 A first example of a head mounted transducer array device 201 is shown. The head mounted device 201 includes a 3D printed frame 203 that is sized to fit around the upper portion of a subject's head. In this example, the 3D printed frame 203 is generally tubular and supports a plurality of ultrasound transducers 205 arranged in an array around the inner circumference of the 3D printed frame 203 so that the ultrasound transducer array surrounds the subject's head when worn. Each ultrasound transducer 205 is communicatively coupled to a ( Figure 1) controller 101. In some embodiments, the 3D printed frame 203 can be customized in size according to the anatomical dimensions of the intended subject. Additionally or alternatively, the positioning and orientation of the ultrasound transducers 205 supported by the 3D printed frame 203 can be adjusted to target one or more specific locations in the brain of the intended subject. In some embodiments, this can be done by manually adjusting the position of the ultrasound transducer 205 to adjust the relative angle of the ultrasound transducer 205, while in other embodiments, the 3D printed frame 203 is configured to receive and support each ultrasound transducer 205 in a positioning and orientation specific to one or more target locations in the brain of the intended subject. In addition, in some embodiments, the relative angle of each transducer in the transducer array is known, so that different target locations can be stimulated by selecting different combinations of ultrasound transducers that intersect at the target location (as described below). Therefore, in some embodiments, it is possible to target close to any brain region by selecting different combinations of ultrasound transducers to transmit ultrasound waves into brain tissue.
[0070] Figure 3 An alternative example of a head mounted transducer array device 301 is shown. In this example, the head mounted device comprises a frame 303 sized to be worn around a subject's head 305 and comprising two separate transducer arrays 307a, 307b positioned on opposite sides of the 3D printed frame. Figure 3 As shown, when the head mounted device 301 is worn by a subject, the ultrasound transducer arrays 307a, 307b are positioned on opposite sides of the subject's head 305. Figure 3 In the example of , the head mounted device 301 also includes an adjustable support mechanism 309 configured for adjustable positioning of a forehead support pad 310 and a nose support pad 311. The forehead support pad 310 and the nose support pad 311 can be adjusted to conform to the anatomical geometry of the head 305 of the intended subject so as to maintain the head mounted device 301 in place during use. In some embodiments, the head mounted transducer array device (e.g., the head mounted device 201 or the head mounted device 301) is constructed of MRI compatible materials and wiring, and as Figure 4 As shown, using the head-mounted transducer array during MRI does not cause any detectable image distortion in the captured MR images. In addition, in some embodiments, the head-mounted transducer array device (eg, head-mounted device 201 or head-mounted device 301) can be waterproof.
[0071] In one configuration, the device 301 includes two spherical phased array transducers mounted to a plastic MRI-compatible frame so that they are positioned relative to each other and separated by a distance of 187 mm. The array elements are made of PMN-PT material, have a surface area of 6 mm × 6 mm, and operate at a fundamental frequency of 650 kHz. The two spherical focusing arrays have a radius of 165 mm, 126 elements in a 9 × 14 element grid, and an inter-element spacing of 0.5 mm. Each array has a height of 55 mm and a width of 86 mm, spanning 47.3 cm 2 area. These transducers are configured to deliver ultrasound through the parietal and temporal bones of the subject. Specifically, the transducers are oriented parallel to the left and right sides of the subject's head. The transducers are driven by a programmable system (e.g., Vantage256, Verasonics). The transducers are coupled to the subject with a hydrogel. Standard ultrasound coupling gel can be applied to the interface between the transducer and the hydrogel and the hydrogel and the head. Given the presence of the hydrogel, the application of ultrasound gel is not critical, but can increase the transmittance by about 2 times.
[0072] In some embodiments, the systems described herein are used to systematically and in a personalized manner diagnose and treat the neural sources of neurological or psychiatric disorders. The head mounted transducer array device 201, 301 is operated to non-invasively modulate the designated brain target with high spatiotemporal resolution and in a multifocal manner. Additionally, in some embodiments, the system is configured to compensate for the skull, thereby depositing a deterministic dose of ultrasound energy into the designated brain target for effective and safe application. In some embodiments, the system is configured to use such as Figure 5A The use shown in the example Figure 3 Ultrasonic energy is applied to the brain target by superimposing ultrasound waves from the head-mounted device 301.
[0073] In some embodiments, the systems described herein are used to activate or release biocompatible nanoparticles carrying one or more therapeutic agents (e.g., propofol) for treating a patient's neurological or psychiatric disorders. The head-mounted transducer array device 201, 301 is operated to non-invasively adjust a designated location in the skull to allow ultrasound to activate and release the therapeutic agent in a designated brain location of the patient. Additionally, in some embodiments, the system is configured to compensate for the skull (e.g., by utilizing the RTT method described herein) to provide a therapeutically effective release to the patient when ultrasound is applied through the skull.
[0074] exist Figure 5AIn the example of , the system is operated to transmit ultrasonic waves from three different ultrasonic transducers of the first ultrasonic transducer array 307a. The ultrasonic waves are emitted at different relative trajectory angles so that the first ultrasonic wave 501a, the second ultrasonic wave 501b, and the third ultrasonic wave 501c all intersect at the target position 503. At the target position 503, the superposition of the three ultrasonic waves 501a, 501b, and 501c results in the application of the expected ultrasonic energy at the target position 503. Once the target position 503 is exceeded, the three ultrasonic waves 501a, 501b, and 501c continue along their respective trajectories until they reach the second ultrasonic transducer array 307b. The output of the transducers in the second ultrasonic transducer array 307b is monitored to determine the delivery intensity of the ultrasonic waves 501a, 501b, and 501c that reach the second ultrasonic transducer array 307b.
[0075] Figure 5A 301 is shown operating in a "free field" region (i.e., where there is only water positioned between the ultrasound transducer arrays 307a, 307b). When the head mounted device 301 is positioned on the head 305, as shown in FIG. Figure 5B As shown, ultrasound waves 501a, 501b, 501c converge at a location within the brain (e.g., target location 503) to apply ultrasound energy via superposition. However, obstacles in the ultrasound path between the first ultrasound transducer array 307a and the second ultrasound transducer array 307b affect the ultrasound waves 501a, 501b, 501c, and in turn affect the ultrasound energy applied at the target location 503. Obstacles in the ultrasound path during use of the head mounted device 301 may include, for example, anatomical features such as the skull and scalp of the subject, hair, a coupling interface between the head mounted device 301 and the head 305, and bubbles in the coupling interface.
[0076] For example, Figure 5C As shown, the ultrasound waves emitted by the first ultrasound transducer array 307a must pass through a portion of the skull 509 before entering the brain and reaching the target location 503 within the brain. Figure 6 An example of the relative intensity of ultrasound energy for each of the three ultrasound waves as the ultrasound waves pass through the skull at 509 is shown. Figure 7 The "expected intensity" at the target location 503 is shown (i.e., Figure 5A The difference between the intensity of the ultrasonic energy at the target location 503 in the free field area of the head mounted device 301) and the "actual intensity" at the target location 503 (i.e., the intensity of the ultrasonic energy at the target location 503 when the head mounted device 301 is worn during use). Figure 8 shows when the head mounted device 301 is worn during use ( Figure 5B ) and has a free field region (as shown in Figure 5A1 ) is measured by the second transducer i of the second ultrasound transducer array 307b at a time when one of the ultrasound waves projected from the first transducer j of the first ultrasound transducer array 307a is measured. These figures show that the presence of the skull and other obstacles along the ultrasound path causes attenuation and phase shifting (e.g., acceleration) of the ultrasound waves. In fact, in some embodiments, the attenuation caused by the human skull prevents the ultrasound waves from generating any significant neural stimulation, an example of which can be seen in Fig.12 It can be observed in the red bar in , for which the compensation proposed in this paper for the skull was not applied. When the compensation in this paper was applied, the neural stimulation was restored.
[0077] In order to achieve the desired amount of ultrasound energy at the target location within the brain, in some embodiments, the electronic controller 101 is configured to determine appropriate compensation for the effects of the skull and other obstructions in the ultrasound path. In some such embodiments, the system measures and compensates for ultrasound attenuation and phase shifting of all obstructions in the ultrasound path using ultrasound itself directly and at the same frequency as that used for treatment. In some embodiments, by comparing ultrasound arrival time and amplitude with the presence of the head ( Figure 5B ) and the head does not exist ( Figure 5A ) to establish the necessary compensation values from a relativistic perspective. By using this mechanism to compensate for all obstacles in the ultrasound path (including, for example, the headset-to-head coupling interface, air bubbles, head anatomy, skull, brain tissue, etc.), the system is able to deliver ultrasound energy to the target location at the same intensity as measured in water (without the head present).
[0078] Fig. 9 An example of a method performed by the controller 101 for determining and applying appropriate compensation to an emitted ultrasound beam to achieve the desired / expected ultrasound energy at a target location within the brain is shown. First, ultrasound energy is measured via a "free field" sequence (step 901), in which ultrasound waves are emitted by a first group of transducers through a "free field" region (e.g., water only between ultrasound transducers) and measured by a second group of transducers on the opposite end of the ultrasound path. Second, the head mounted device 301 is positioned on the head and a "through transmission" sequence is measured (step 903), in which the same ultrasound waves are emitted from the first group of the same transducers and measured by the second group of the same transducers; however, in the "through transmission" sequence, the ultrasound path travels through the subject's head / skull. The measurements from the two sequences are compared to quantify the attenuation and phase value differences (step 905). Appropriate phase and amplitude adjustments are determined based on the attenuation and phase value differences (step 907). The determined amplitude and phase adjustments are used to apply the ultrasound waveform to each transducer (step 909). Additional details surrounding the "pass-through" approach are described below in Example 2.
[0079] Relative to measurements in water (e.g., free-field sequence measurements), obstacles in the ultrasound path (e.g., the skull) attenuate the beam emitted from each transducer element i by A i times and accelerates the beam relative to time . Fig. 9 The compensation method estimates these values and corrects them, converting the amplitude of each ultrasonic beam to factor and delay the emission In some embodiments, the acceleration time is solved separately and attenuation A i reconstruction.
[0080] For attenuation, in some embodiments, the controller 101 is configured to solve the system of equations: (1) Among them, A ij is the relative attenuation value for ultrasound propagating through the two sides of the skull as measured by the through-transmission method. The proportionality constants in these equations are represents the extended path of ultrasound through the skull at the angle β between transducer elements i and j. The attenuation values through two opposite segments of the skull are multiplied, thus giving a logarithmic formula for the attenuation. This system of linear equations can be expressed in matrix form as K x = b, where K is k ij The matrix of coefficients, x is the value sought x = [A1, A2, . . . , A 256 ], and b is the measured value A ij The solution x minimizes the squared error sum.
[0081] In some embodiments, the controller 101 is configured to calculate the phase shift as follows For all converter pairs, h ij (t) corresponds to the signal received at the i-th transducer after a short pulse is sent from transducer j. (i.e., free-field measurements) and through the skull For each receiving transducer i in the N total transducers, the controller 101 determines the focus on all transmit-receive waveforms. Water on the element i (i.e., free-field measurement).
[0082] Time-shift The sum of these waveforms for any vector is expressed as: (2) in: (3)
[0083] The goal is to find the delay that accounts for the acceleration of the water . Applying a delay To compensate for the acceleration ahead of the transmitting element, each wave received at element i in the water should be delayed compared to the wave passing through the skull In some embodiments, the controller 101 is configured to identify these delays by optimizing the equation : (4)
[0084] Fig.10 Shown by Fig. 9 The intensities produced by the compensation method at three different target locations within the brain: the supero-lateral branch of the medial forebrain bundle, the ventral capsule / ventral striatum, and the ventral intermediate nucleus (VIM). For each experiment, the graph shows the intensity of ultrasound energy at the target location without the skull (i.e., free-field measurement), the intensity at the same target location when the same ultrasound beam is applied through the skull (i.e., through-transmission measurement), and the intensity at the same target location when the compensated ultrasound beam is applied to the head (i.e., "Diadem-corrected" stimulation measurement). The graphs represent quantification of the compensation accuracy in eight different samples, mean + / - sem. As shown in these graphs, the expected peak intensity delivered to each target (14 W / cm 2 ) is severely attenuated by the skull for all targets (see Fig.10 However, Fig. 9 The compensation method can accurately restore the expected intensity value (see Fig.10 green bar in the .
[0085] Fig.11 and 12 Shows the use of Fig. 9Results of another set of experiments using a compensation method for head mounted devices 301 were configured to target nerves and nerve endings in the thumbs of 11 participants. The thumb was secured to the VIM inside an ex vivo skull. The device delivered 300 ms stimulation to the target site at a frequency of 650 kHz. Data was collected without a skull, through an ex vivo skull, and through the skull after corrections were applied to the skull. The experiment also included applying 10 mm stimulation below the finger (i.e., "off-target" sham stimulation). The subjects closed their eyes and wore noise canceling headphones. The subjects were blinded to whether correction, no correction, or sham stimulation was applied, and reported any noxious responses. Noxious responses are an indication of stimulation of nerves and nerve endings.
[0086] Fig.11 The graph of shows the dose-response relationship of the stimulation. Two-way ANOVA detected a significant modulation of ultrasound pressure (F(2,60)=25.11, p<0.001). Correction for the skull was accurate, as there was no significant difference between the response to stimulation without the skull and the response to stimulation with the skull correction (p=0.96). Fig.12 The graph shows the quantification of the effect at the highest applied stimulation pressure (1.33 MPa). The p value provides the significance of the corresponding two-tailed t test. Fig.12 As shown, the percentage of responses for no skull stimulation and skull-corrected stimulation are almost the same, while the percentage of responses for uncorrected stimulation applied through the skull is almost zero. This result clearly demonstrates the importance of compensation; without compensation, there is essentially no neural stimulation. Additionally, the percentage of responses for off-target stimulation is also almost zero - suggesting that the stimulation applied by the head-mounted device 201, 301 may not have a discernible stimulation effect outside the intended target area.
[0087] Fig.13 and 14 Results of yet another stimulation experiment using a head-mounted transducer array device are shown. Fig.13 The measured peak pressures at each of the three different target sites (ventral tegmental area (VTA), ventral capsule / ventral striatum (VC / VS), superior lateral branch of the medial anterior bundle (slMFB)) are shown for free-field measurements (i.e., “Expected (when no skull)”), uncompensated through-target measurements (i.e., “Actual (due to skull)”), and compensated through-target measurements (i.e., “Compensated (US-corrected)”). This figure confirms that Figures 10 to 12 The concept of Fig. 9 The compensation procedure described in is critical for deterministic and effective ultrasound dose delivery. Fig.14 Quantification of focal volumes for the same three target regions under the same three stimulation conditions is shown. Fig.14As shown, the presence of skull bones within the ultrasound path not only attenuates ultrasound waves, but also increases the focal volume of stimulation provided by the superimposed ultrasound beam. Fig.14 It is also shown that it is possible to Fig. 9 The method applies compensation to reduce the focal volume. Therefore, Fig.14 It is shown that, in addition to compensating for the attenuation and phase shift caused by obstacles in the ultrasound path, the above reference Fig. 9 The methods described in the examples can also be applied to adjust and tune the focal volume of the applied stimulation. In some embodiments, the controller 101 is configured to coordinately optimize the compensation of the adjustments applied to the transmitted ultrasound beam so that both the corrected peak pressure and the focal volume are as close to the expected values as possible. Under some conditions, adjustments that bring the focal volume closer to the target can move the corrected peak pressure further from the peak pressure target. The controller 101 can use a variety of different optimization techniques to determine an optimized solution for balancing deviations from the peak pressure and focal volume targets when both targets cannot be achieved simultaneously.
[0088] Fig.15 An alternative example of a head mounted transducer array device 301 is shown. In this example, the head mounted device includes a frame sized to be worn around a subject's head and includes two separate transducer arrays (black) positioned on opposite sides of the frame. Figure 3 As shown, when the head mounted device is worn by a subject, the ultrasound transducer arrays are positioned on opposite sides of the subject's head. Figure 3 In the example of , the head mounted device 301 also includes an adjustable support mechanism configured for adjustable positioning. In some embodiments, the head mounted transducer array device (e.g., the head mounted device 201 or the head mounted device 301) is constructed of MRI compatible materials and wiring, and as Fig. 17C -G and Fig.33 As shown, using a head-mounted transducer array during MRI does not cause any detectable image distortion in the captured MR images. In addition, in some embodiments, the head-mounted transducer array device can be waterproof.
[0089] Example 1: Demonstration of effective neuromodulation using a head mounted device in humans.
[0090] The device was applied to patients with treatment-resistant depression to modulate a deep brain structure, the subgenual cingulate cortex. Engagement of the target using fMRI BOLD was verified. Furthermore, modulation of the target improved the patient's emotional state. The effect was specific to the stimulated target and was not observed during sham stimulation, which was delivered to the brain with the same pressure and waveform but in a non-focused manner.
[0091] Will Figure 5BThe head mounted device 301 shown in FIG. 1 is applied to a patient (see Fig.15 ). The device includes two sets of 126-element phased array transducers located at opposite sides of the patient's head. The transmit-receive capability of each transducer array element enables ultrasound-based correction for attenuation (and dephasing) of each ultrasound beam. A single preoperative MRI and mechanical registration are used to direct transcranial application of focused ultrasound to multiple regions of the patient's brain. When focused at a target in the subgenual cingulate cortex, the array produces an intensity field with focus dimensions of 20.4 mm axial, 2.4 mm lateral, and 3.6 mm vertical (see Fig.16 ), with a total volume of 142.71 mm 3 , the equivalent volume of a sphere with a diameter of 6.48 mm.
[0092] Fig.17A -B shows the intensity field produced by the array overlaid on the subject's brain anatomy to scale. The phased array geometry allows flexible, electronic steering of the focus to ±45 mm, ±25 mm, and ±15 mm in the axial, lateral, and vertical dimensions, respectively ( Fig.23 MRI-compatible plastic frame (eg Fig.15 ) holds the array and slides on horizontal and vertical tracks; allowing the array to be translated and then locked into any position on the side of the subject's head.
[0093] After skull registration and ultrasound-based correction, the fMRI BOLD response was measured. Fig. 17C -G while sonicating the subgenual cingulate cortex of the brain. Fig. 17C and 17D Significant bold activation was shown at the targeted region (peak level: p=0.003, t=5.52, ZE=5.37, cluster level p<0.001 (family-weighted error correction, kE=69 voxels)). This fMRI BOLD activity was specific to the onset of ultrasound stimulation ( Fig.17E Contrast estimates of BOLD activity in this region from ultrasound-off to ultrasound-on conditions showed a large effect size of 3.07±0.56 (mean±sem). Subjects who were blinded to the type of stimulation were also presented with active sham stimulation of unfocused plane wave ultrasound as a negative control. The unfocused beam consisted of the same stimulation parameters and intensity, but the phase delay was adjusted to focus the energy outside the subject's head. No significant BOLD activity was measured near the target site under this active sham condition ( Fig.17F -G).
[0094] Outside the MRI scanner, 10 subjects were presented with ultrasound treatments with varying stimulation durations and focal positions at a pressure of 1 MPa, a pulse duration of 30 ms, and an interpulse interval of 4 seconds. When the subgenual cingulate gyrus was ultrasound treated for durations of 150 and 300 seconds ( Fig.18 ), improvements in subjects’ self-reported ratings of depression, anxiety, and valence were observed when ultrasound was administered to the ventral striatum or when ultrasound was administered using unfocused plane wave stimulation of the same intensity. Subjects reported no changes in mood when ultrasound was administered to the ventral striatum or when ultrasound was administered using the same intensity. The effects were also specific to stimulation duration: changes in mood ratings increased with increasing stimulation duration. Stimulation lasting less than 150 seconds produced almost no changes in mood ratings. In addition to these effects on mood, subjects also reported being able to maintain thoughts for longer periods of time while stimulated for the first time in two weeks and having the subjective experience of being hopeful about future events. Importantly, subjects did not report any adverse effects during the three 90-minute-long ultrasound sessions (Table 1). Table 1
[0095] Prior to sonicating a specific target, through-transmission measurements of the subject are acquired, the attenuation and phase delay in front of each element compared to water are estimated, and stimulation parameters are adjusted to correct for these ultrasound aberrations. Figure 5A-5C , Figure 6 , Figure 7 , Figure 8 A- Figure 8 B and Fig.19 The steps involved in the correction and example through-transmission waveforms taken through water and through a subject are shown. It takes less than a second to capture the entire through-transmission scan across all 252 elements. Critically, the scan measures the attenuation from all sources in the beam path: coupling, hair, local air pockets, skull, and brain. Instantaneous measurement of pressure transmission through the skull at each element informs the operator of the acoustic coupling quality and allows them to fix decoupling elements prior to sonication. Fig. 20 The average amplitude scaling factors applied to the transducer elements to compensate for the estimated attenuation are shown. The average amplitude scaling factors were 4.84 ± 0.94 (mean ± SD) for stimulation period 1, 5.59 ± 1.09 for period 2, and 5.68 ± 0.97 for period 3. Any element with less than 12% of the estimated pressure transmission was turned off, and the remaining elements increased their amplitudes to compensate for the loss contribution of that element.
[0096] Finally, to assess targeting reproducibility, the targeting error of the device was measured across multiple sessions and subjects. The plastic frame allowed for repeatable positioning of the ultrasound transducer. Across all sessions and subjects, ultrasound transducer positioning varied by a total of 0.89 ± 0.64 (mean ± SD) and was 0.45 ± 0.32, 0.43 ± 0.14, and 0.44 ± 0.17 in the x, y, and z dimensions. The thermoplastic mask reliably secured the subject's head in the same positioning across sessions. Fiducial markers on the subject varied by a total mean of 1.28 ± 0.66 in positioning and were 0.53 ± 0.19, 0.68 ± 0.27, and 0.71 ± 0.31 (mean ± SD) in the x, y, and z dimensions across all subjects and trials. Fig.21 Targeting error—the deviation between the position of the hypothetical ultrasound focus and the brain target of interest—was assessed by measuring the mean positioning difference between the fiducials on the subject and the fiducials on the ultrasound transducer. In total, the devices had a mean targeting error of 1.64 ± 0.66 across subjects and 0.77 ± 0.50, 0.93 ± 0.41, 0.99 ± 0.49 ( Fig. 22 ).
[0097] The study described in this example validates the device's effectiveness by inducing significant changes in fMRI BOLD activity at the targeted region. The device improves upon current ultrasound neuromodulation techniques by correcting for attenuation and phase shifts caused by the subject's skull, hair, and acoustic coupling; thereby delivering effective and safe intensities at the target site. Fig.33 (left) indicates that this function is essential for effective ultrasound neuromodulation. When not applied ( Fig.33 , right), with no neuromodulatory effect in the presence of existing ultrasound devices.
[0098] The mechanical frame and phased array system enable flexible focusing of energy into spatially specific targets throughout the deep brain. Using a novel mechanical registration approach, the device achieves reproducible targeting of deep brain regions across subjects and treatment sessions outside of the MRI scanner without the need for expensive neuronavigation systems.
[0099] The device provides effective neuromodulation in humans, which can be monitored by fMRI BOLD measurements. When the subgenual cingulate cortex in human subjects was stimulated, a clear fMRI bold response at the target was evoked. Changes in fMRI BOLD activity were time-locked to ultrasound stimulation and were absent during sham stimulation. Together, these data provide strong evidence that the device clearly activates deep brain targets and that the response is specific to ultrasound stimulation. The fMRI BOLD readouts available with this MRI-compatible device give valuable feedback on neuromodulation amplitude, polarity, and targeting accuracy. Using stimulation parameters in an MRI scanner, it was found that stimulation was targeted and suppressed activity in the subgenual cingulate cortex.
[0100] Modulation of the subgenual cingulate cortex effectively induced positive changes in the subjects' emotional state. Specifically, improvements in the subjects' self-reported scores of depression, anxiety, and valence were observed. Subjects did not report changes in mood in response to sham stimulation, stimulation of the ventral striatum, or most stimulations lasting less than one minute. In summary, changes in mood were specific to the targeted area (subgenual cingulate gyrus) and stimulation parameters (duration greater than one minute). Stimulation from the device was safe and well tolerated. Subjects reported no adverse reactions during three 90-minute stimulation sessions.
[0101] The ability of a device to measure the attenuation of an ultrasound beam is important for both safety and effectiveness ( Fig.33 ). Ultrasound attenuation varied across sessions. These differences are likely due to variability in the coupling of the transducer to the subject's head due to repeatable positioning of the device over the same segment of the skull. A safety feature of the device is to shut down elements that experience particularly high attenuation - this can be the result of localized cavitation or particularly thick areas of the skull. In either case, the sonication can result in dangerous cavitation or heating effects. Regarding effectiveness, the large amplitude scaling factors applied to the array elements as well as phase correction are critical to the stimulation. When titrating the dose, several sonications were delivered through the skull at a delivery pressure of 0.4 MPa and no changes in mood scores were seen. Given the average pressure-amplitude scaling factor of 5.37 for this particular subject, if correction for the skull did not occur, the expected intensity would be 33.78 W / cm 2 (1MPa), will deliver less than 1.09W / cm 2(0.18 MPa) intensity. CT correction is for the skull, which is effective for measuring skull-induced dephasing, but not for attenuation, which does not account for attenuation due to hair, trapped bubbles, and variability in acoustic coupling. These additional impairments are considerable, with the transmit intensity attenuated by about 0-64% due to coupling, about 20% due to hair, and up to 100% due to localized bubbles or cavitation. For example, in some sessions, as many as 60 of the 252 elements were found to not be acoustically coupled to the object prior to sonication, and this coupling problem had to be corrected prior to sonication. The remaining uncoupled elements were turned off. This feedback is not present with CT correction, and would result in potentially dangerous sonications with localized cavitation and less than effective pressure at the target.
[0102] The flexible and reproducible targeting of the device allows intervention across many areas of the brain ( Fig.23 ). To engage the subgenual cingulate gyrus in this subject, the beam was electronically steered 17 mm laterally and 9 mm vertically from the geometric center of the array. With the array locked in place and electronic beamforming used, the subgenual cingulate cortex, the superior and inferior segments of the ventral striatum were sonicated, and the beam was steered to the outside of the head for sham stimulation during all identical stimulation sessions. With the ability to beamform different targets in microseconds, phased array systems are able to stimulate hundreds of unique brain regions per minute. Other areas of the brain—such as the thalamic nuclei, amygdala, cingulate cortex, insular cortex, nucleus accumbens, ventral tegmental area, etc.—can be addressed by a combination of physical movement of the array and forming the focal beam to a given target. This rapid, flexible targeting is unique to phased array systems. Devices used for neuromodulation are typically targeted using MRI-guided single element transducers or using optical neuronavigation. Mechanical registration methods allow accurate targeting of deep brain regions both inside and outside of MRI scanners, and do not require those more expensive registration tools.
[0103] Although robust fMRI BOLD activity in response to stimulation has been shown in animal studies, only two groups have reported fMRI measurements in humans. These results are extended by showing the first demonstration of fMRI BOLD response to ultrasound stimulation of the subgenual cingulate gyrus, a relatively deep region, and a relatively strong effect size. The strong fMRI activation is due to increased pressure at the target site obtained from correcting for skull aberrations ( Fig.33 Together, these striking, time-locked BOLD responses to ultrasound stimulation illustrate key features of the device for monitoring neuromodulatory effect size, polarity, and targeting accuracy.
[0104] This study also demonstrates that first-time tFUS stimulation of the subgenual cingulate cortex improves mood states in treatment-resistant depressed patients. Previous studies have similarly shown improvements in mood with FUS stimulation of the ventral prefrontal cortex and inferior prefrontal cortex. Immediate improvements in mood were observed as well as subjective effects, such as hope for future events. The rationale for targeting the subgenual cingulate gyrus derives from previous DBS studies and neuroscience literature showing that this area is associated with major depressive disorder. The results of this study support the view that the SGC regulates mood states and is a promising target for longer duration FUS stimulation.
[0105] The fMRI and emotional response results of this study were limited to a single subject in an ongoing clinical trial with a total of 20 subjects. However, the fMRI results were statistically significant compared to baseline, and the emotional effects could be reproduced across time periods and were robust to sham stimulation; therefore these data illustrate proof of concept in the first human subject of this trial. The stimulation targets in this first subject were limited to the ventral striatum and the subgenual cingulate cortex. Due to the rapid and flexible beamforming of ultrasound, multiple targets within the medial forebrain bundle, ventral tegmental area, and anterior cingulate cortex as unique brain targets can be sonicated almost simultaneously in a rapid sequence. The device is limited to through-sounding areas of the skull where a through-transmission path can be established; i.e., the left and right sides of the head. Therefore, although the device can access almost the entire subcortical volume of the brain through mechanical translation of the array and phased array steering, it has limited access to cortical brain targets.
[0106] A non-invasive device capable of controlling ultrasound delivery for safe and effective deep brain stimulation has been described herein. The pairing of ultrasound stimulation with fMRI enables direct monitoring of neuromodulation. Regarding practicality, a single T1 MRI of the patient's head inside the device is required for accurate targeting of all subsequent ultrasound treatments. Additionally, there is no need to shave the head. The phased array system is able to adjust the stimulation position within the brain with millimeter accuracy in microseconds and stimulate hundreds of unique brain targets per minute. Compared with existing FUS brain stimulation (BXPulsar, NeuroFUS) or surgical (Exablate Neuro) devices, this is the only device with the ability to compensate for the attenuation of the human skull, hair, and variable acoustic coupling. This ability is critical because each obstacle severely and unpredictably distorts and attenuates ultrasound. Any future low-intensity application of ultrasound to the brain must address this issue so that the ultrasound energy delivered to the target is safe, effective, and reproducible between patients. Accurate correction of these distortions by the device is expected to greatly improve not only the safety and efficacy of neuromodulation, but also other low-intensity applications of transcranial focused ultrasound, such as local drug delivery and blood-brain barrier opening, which, like ultrasound neuromodulation, are highly dependent on the intensity of delivered ultrasound.
[0107] Example 2: Testing RTT accuracy and validity
[0108] Fig.24 A demonstrates the severity of acoustic attenuation by the skull. Across eight ex vivo skulls, ultrasound intensity delivered to deep brain locations was found to be attenuated by a factor of 11.4 ± 6.8 (mean ± SD), replicating previous findings. In principle, attenuation could be estimated using tabulated values (e.g., 20, 21), but the high variability of attenuation across individuals makes such estimates inaccurate and uncertain ( Fig.24 B). For example, using the values from these two studies would over- and under-estimate the mean by factors of 1.7 ± 0.67 and 0.63 ± 0.25, respectively, and result in high variability (pooled standard deviation equal to 0.47 compared to a normalized intensity of 1.0). Compensation for ultrasound dephasing that can be obtained using existing methods can be used for ultrasound-based surgery and also for the current purpose of delivering deterministic intensity into a specified target for repeated applications ( Fig.24 C). Nevertheless, even with an assumed ideal correction of the phase based on true value measurements ( Fig.24 C) also leaves an average difference of 85% between the expected intensity and the actual intensity delivered to the brain target.
[0109] When ultrasound is focused into a specific target inside the human skull, Figure 1 A's system and Figure 5AThe device shown in is used to test the accuracy of the above RTT. The sensing field using the hydrophone is measured. The measured intensity under four conditions is evaluated. First, the intensity in the free field is measured, where there are no obstacles to the ultrasound. This intensity corresponds to the intensity intended to be delivered by the operator into the target. Second, the skull is positioned between the device and the hydrophone, and the resulting intensity is measured. This situation presents the worst-case scenario with no correction for the skull. Third, the assumed ideal correction for the skull is evaluated. For this purpose, the hydrophone is used to measure the attenuation and phase shift of each element of the device, thereby obtaining true values. These true values are used to compensate for these aberrations, scaling the amplitude of the ultrasound emitted from each element and delaying it accordingly, as if there were no skull. Fourth, the RTT correction is applied.
[0110] These measurements were performed in eight water-immersed, degassed human excised skulls. Fig.25 The spatial peak intensity and associated field for a target positioned at the center of the two transducers are shown. The figure reinforces the concept that the human skull severely suppresses the intensity delivered to the brain (red). The ultrasound intensity through the skull was attenuated 11.4 ± 6.8 (mean ± SD) times compared to the free-field value, degrading it to 10.7 ± 4.2% of the expected intensity. The difference between the free-field and through-skull values was significant (t7 = 60.7, p = 8.6 × 10-11, paired two-tailed t test).
[0111] Next, RTT using a phased array was applied. Fig.25 The RTT restores the expected intensity values (green). The RTT compensated intensity constitutes 98.8±17.8% (mean±SD) of the expected value in the free field, and there is no significant difference between the means of the two conditions (t7=0.18, p=0.86, paired two-tailed t test). The means are not significantly different compared to the hypothetical, best possible correction based on the true value measurements of the hydrophone inside the skull (black bars; t7=0.17, p=0.86, paired two-tailed t test). One skull (purple data point) severely attenuates ultrasound (26.9 times attenuation). As assessed by the neurosurgeon, this may be due to the visual appearance of an outgrowth that may be related to bone hyperplasia. For this skull, the accuracy of the RTT correction is low, reaching 0.62 times the expected intensity.
[0112] Next, we evaluated whether RTT could be applied to the human head, which presents additional critical obstacles to transcranial ultrasound, including hair, scalp, acoustic coupling, and brain. This test also evaluated the safety of the method. RTT is designed to be safe. RTT scans consist of brief (<100μs) low-intensity (average peak pressure of 80kPa in free field) ultrasound pulses. RTT scans take less than one second to complete. Subjects (n=5) did not feel any discomfort during the procedure. Fig.26 The blue figure shows the average through-transmission attenuation through the two sides of the head separately for each subject. The figure illustrates that this method provides through-transmission quality comparable to that of an ex vivo skull (grey). Specifically, when RTT was applied through the human skull, the receiving elements on the opposite sides of the head recorded an average of 7.3±4.8% (mean±SD, n=5 subjects) of the signal amplitude, and 12.6±8.2% (mean±SD, n=8 skulls) was recorded for the characteristic ex vivo human skull. The additional 1.7-fold attenuation is expected because applying ultrasound through the human head causes additional attenuation by the hair, scalp, connectors, air bubbles or air pockets between them, and tissue inside the skull. No subjects reported side effects at the 1-week follow-up. Therefore, RTT can be safely applied to the human head and directly measures the attenuation of all obstacles within the ultrasound path.
[0113] Next, the robustness of the RTT relative to the location of the brain target was tested. To do this, a phased array was used to refocus ultrasound into a target that covered the full steering range of the device: 10 mm axial, 20 mm axial, 10 mm lateral, 20 mm lateral, and 15 mm vertical from the central target ( Fig. 27 RTT correction resulted in delivered intensities of 96.3 ± 21.4%, 94.8 ± 23.2%, 92.8 ± 16.4%, 62.5 ± 15.7%, and 71.6 ± 18.03% of the expected values in each target, respectively. There was no statistical difference between the mean of the expected peak intensity and the RTT-compensated peak intensity at the central target (t7 = 0.18, p = 0.86, paired two-tailed t test), 10 mm axial (t7 = 0.48, p = 0.64, paired two-tailed t test), 10 mm lateral (t7 = 0.42, p = 0.55, paired two-tailed t test), and 20 mm axial (t7 = 1.23, p = 0.26, paired two-tailed t test). There were significant differences in mean delivered intensities at 20 mm lateral (t7=6.748, p=0.0002, paired two-tailed t test) and 15 mm vertical (t7=4.5, p=0.003, paired two-tailed t test) to the target.
[0114] Subsequently, the relative contributions of the two key components of ultrasound aberrations of the skull – attenuation and phase shift – were tested. Fig.28The spatial peak intensities after engagement of each correction type in isolation and in their combined application are shown. At the central target, phase correction alone results in a mean intensity of 13.8 ± 4.3% (mean ± SD) of the ideal hydrophone correction (grey) and a mean intensity of 11.9 ± 4.9% of the RTT (green). The no correction value (red) is 10.7 ± 4.2% of the free field intensity. Amplitude correction alone results in a peak spatial intensity of 71 ± 12.5 for the hydrophone and 93.8 ± 28.9 for the RTT. Therefore, correction for attenuation (i.e., for the amplitude of the received signal) constitutes a critical factor in the delivered ultrasound intensity. The inclusion of correction for phase is additionally desirable because the resulting combined correction ( Fig.28 (at c)) resulted in an average delivery intensity of 98.8±17.8%.
[0115] The robustness of RTT with respect to specific hardware was further tested. Specifically, RTT was implemented on an array with the same number of apertures but much larger ( Fig.29 ). For this configuration, the skull (n = 4 samples) degrades the intensity at the geometric center to 6.3 ± 1.7% of the expected free-field value, consistent with Fig.24 Consistent.
[0116] RTT compensation restored the intensity at the target site to 104 ± 18.1% of the expected value. After compensation, there was no significant difference between the expected and mean RTT restored intensities (t3 = 0.47, p = 0.67, paired two-tailed t test).
[0117] Example 3: Demonstrate effective application of transcranial ultrasound for neuromodulation in humans using a head-mounted device.
[0118] To test the effects on nerves within intact biological tissue, 11 human subjects were instructed to place their thumbs into a holder at a central target inside an ex vivo skull. The subjects' responsiveness to ultrasound was quantified when RTT was applied and when RTT was absent (see Methods). The target received specific pressure levels for 300ms stimulation, and the effects on the subjects' nociceptive responses were assessed. Nociceptive responses indicate stimulation of nerves or nerve endings in tissue. RTT was found to be critical for effective stimulation ( Fig.30 (a). In the absence of RTT, there was no significant stimulation (red; t11 = 1.00, p = 0.34, one-sample two-tailed t test). After RTT, subjects responded to stimulation at a rate of 62.7%. This level was statistically equivalent (t10 = 0.58, p = 0.57, paired two-tailed t test) to the 66.3% response rate obtained using the assumed best possible true value correction, which is as good as the absence of the skull. Fig.31 Individual responses to each correction for all subjects are shown.
[0119] To control for potential confounds that may be associated with ultrasound stimulation, sham stimulation of ultrasound delivered 10 mm below the target with hydrophone correction was randomly interleaved. This off-target stimulation did not produce significant stimulation (yellow, p=0.19, one-sample two-tailed t test, t11=1.39). This control was used for potential processing effects and confirmed the spatial specificity of the stimulation.
[0120] The dose dependence of the stimulation effect was further investigated. Specifically, stimulation was varied across three intensity levels. It was found that the stimulation effectiveness increased with increasing ultrasound levels ( Fig.30 (b)). The response frequency reached 62.7% for the strongest (1.8 MPa) stimulus and was also significant for the weakest stimulus tested (1.3 MPa; t10 = 7.63, p = 1.7 × 10-5, one-sample two-tailed t-test). The effect of stimulus level was highly significant (two-way ANOVA, F2,60 = 25.24, p = 1.1 × 10-8). Responses were statistically indistinguishable from the assumed ideal correction (green vs. black; two-way ANOVA, F1,60 = 0.41, p = 0.52), and there was no significant interaction between the two factors (F2,60 = 0.20, p = 0.98).
[0121] Therefore, accurate compensation of delivery intensity to the brain target ( Fig.25 , Fig. 27 ) also translates into stimulus effectiveness for reinstatement, where response levels cannot be obtained without the RTT method described in this paper ( Fig.30 ).
[0122] The measurements and compensation of the human head described in this article are critical for effective ultrasound neuromodulation in the human brain. Fig.33 The left side shows compensation of the head to achieve strong ultrasonic neuromodulation. Fig.33 The right side shows that when this compensation is not applied, as is the case using prior devices and methods, there is no significant ultrasonic neuromodulation.
[0123] Example 4: Demonstrating the effective application of transcranial ultrasound for drug release using a head-mounted device in humans.
[0124] It was tested whether RTT can be used to release therapeutic agents (e.g., any hydrophobic drug such as propofol, mycophenolate, and ketamine) at specific locations inside the skull at clinically relevant and deterministic doses. In one example, ultrasound-sensitive nanoparticle carriers were designed and the neuromodulatory drug propofol was encapsulated in the nanoparticles at a concentration of 0.063 mg / ml. Fig.30The researchers tested how the nanoparticles responded to ultrasound when an RTT correction was applied and how they responded to ultrasound when it was not applied. They found that RTT was key to mediating effective release when ultrasound was applied through the skull ( Fig.32 (a) In the absence of RTT (red), the amount of drug detected was not different from the no-stimulation condition (purple) (t14 = 0.30, p = 0.77, two-sample two-tailed t-test). Application of RTT (green) almost tripled the release effect (2.9-fold increase), releasing 31.6% of the encapsulated propofol. This level was statistically equivalent (t18 = 0.08, p = 0.94, paired two-tailed t-test) to the 31.8% release obtained using the assumed best possible correction (black).
[0125] The spatial specificity of release was confirmed using sham conditions, in which ultrasound was focused 10 mm below each vial ( Fig.32 (a)). In this case, the amount of drug detected was no different from the case where no ultrasound was applied (purple) (t14=0.30, p=0.77).
[0126] The dose dependence of release was also investigated. For this purpose, the delivered ultrasound intensity was varied with Fig.30 It was observed that the stimulation effectiveness increased with increasing ultrasound level ( Fig.32 (b) The effect of stimulation level was highly significant (two-way ANOVA, F2,54 = 84.53, p = 2.3 × 10-17). Release level was statistically indistinguishable from the hypothesized ideal correction (green vs. black; two-way ANOVA, F1,54 = 0.02, p = 0.89), and there was no significant interaction between the two factors (F2,54 = 0.35, p = 0.7).
[0127] Therefore, accurate compensation of delivery intensity to the brain target ( Fig.25 , Fig. 27 ) also translates into restored stimulus effectiveness, whose response levels would not be obtained without the method ( Fig.30 ). In other words, the expected ultrasound intensity is sufficient to activate the microbubbles and thus temporarily disrupt the blood-brain barrier for local delivery of drugs, genes and stem cells across the blood-brain barrier.
[0128] Thus, in various embodiments, the present disclosure provides, among other things, systems and methods for using ultrasound to apply focused ultrasound to a location in the brain and using the ultrasound itself to accurately compensate for attenuation, phase shifts, and / or focal volume changes due to the presence of the head in the ultrasound path. Additional features and advantages of the invention are set forth in the following claims and drawings.
Claims
1. A method for applying ultrasound to a target brain location, the method comprising: driving at least one transmitting ultrasound transducer for generating ultrasound waves to achieve a desired ultrasound stimulation energy at a target location in a free-field volume, the target location in the free-field volume corresponding to the target brain location; measuring the ultrasonic waves using at least one receiving ultrasonic transducer positioned on opposite sides of the free-field volume at a fixed distance and orientation relative to the at least one transmitting ultrasonic transducer; positioning the at least one transmitting ultrasonic transducer and the at least one receiving ultrasonic transducer on opposite sides of the head, wherein a stationary distance and orientation of the at least one receiving ultrasonic transducer relative to the at least one transmitting ultrasonic transducer remains fixed; driving the at least one transmitting ultrasound transducer to generate the ultrasound wave into the head, wherein the ultrasound wave is the same ultrasound wave generated to achieve the desired ultrasound stimulation energy at a target location in a free field volume; measuring, using the at least one receiving ultrasonic transducer, altered ultrasonic waves exiting the head, wherein the altered ultrasonic waves are attenuated and phase shifted due at least in part to the presence of the head in an ultrasonic path between the at least one transmitting ultrasonic transducer and the at least one receiving ultrasonic transducer; determining one or more adjusted ultrasonic waves based on a difference between the measured ultrasonic waves passing through the free-field volume and the measured altered ultrasonic waves passing through the head, wherein the one or more adjusted ultrasonic waves are adjusted to compensate for the attenuation and the phase shift caused by obstacles in the ultrasonic path so as to make the actual ultrasonic stimulation energy at the target brain location close to the expected ultrasonic intensity at the target brain location; and The at least one transmitting ultrasound transducer is driven to generate the one or more modulated ultrasound waves into the head at the desired ultrasound intensity.
2. The method of claim 1 , further comprising identifying a group of ultrasound transducers from the ultrasound transducer array, wherein: The ultrasound transducer array includes a plurality of ultrasound transducers, each ultrasound transducer being positioned and oriented to project an ultrasound beam along a different ultrasound path, wherein the identified set of ultrasound transducers includes ultrasound transducers having ultrasound paths that intersect at the target brain location, and Wherein, driving the at least one transmitting ultrasonic transducer for generating the ultrasonic wave to achieve the expected ultrasonic stimulation energy at the target brain location includes driving the ultrasonic transducer in the identified group of ultrasonic transducers to emit ultrasonic waves, and the ultrasonic waves are combined to generate the expected ultrasonic stimulation energy by superposition at the target brain location.
3. The method of claim 1 , further comprising determining the attenuation and the phase shift caused by the ultrasound wave passing through the head once based in part on a difference between the measured ultrasound wave passing through the free field volume and the measured altered ultrasound wave passing through the head, wherein The differences are indicative of the attenuation and phase shift caused by the ultrasound wave passing through each segment of the skull.
4. The method of claim 1, further comprising determining a skull attenuation of a first ultrasonic wave transmitted by a first ultrasonic transducer of the at least one transmitting ultrasonic transducer, wherein: The skull attenuation is based at least in part on the measured altered attenuation of the ultrasound wave due to the ultrasound wave passing through the skull once, Wherein determining the one or more adjusted ultrasound waves comprises scaling the amplitude of the first ultrasound wave by a factor of the multiplicative inverse of the determined skull attenuation of the first ultrasound transducer.
5. The method according to claim 4, wherein: Determining the skull attenuation of the first ultrasound wave includes calculating the skull attenuation of the first ultrasound wave according to: Among them, A ij is the attenuation of the first ultrasonic wave caused by the first ultrasonic wave passing through both sides of the skull, and A i is the skull attenuation of the first ultrasound wave caused by the first ultrasound wave entering the head through the first side of the skull, A j is the attenuation of the first ultrasound wave due to the first ultrasound wave leaving the head through the second side of the skull, and k ij is the multiplicative inverse of the cosine of the relative angle of the ultrasonic beam emitted by the first ultrasonic transducer.
6. The method according to claim 1, wherein: Driving the at least one transmitting ultrasonic transducer includes driving a plurality of ultrasonic transducers, the method further including determining a plurality of skull attenuation values, the plurality of skull attenuation values including a determined skull attenuation value of each of the plurality of ultrasonic transducers, wherein each skull attenuation value of the plurality of skull attenuation values indicates attenuation caused by an ultrasonic wave transmitted by a corresponding ultrasonic transducer passing through the head once, Wherein, determining the one or more adjusted ultrasonic waves comprises scaling the amplitude of the ultrasonic wave emitted by each of the plurality of ultrasonic transducers by a factor corresponding to a multiplicative inverse element of a determined skull attenuation value of the ultrasonic transducer.
7. The method according to claim 1, wherein: The modified ultrasonic wave exiting the head includes an amplitude and a phase that are scaled and delayed so that the modified ultrasonic wave received during the through-the-skull measurement approaches the ultrasonic wave received during the free-field measurement.
8. An ultrasound delivery system comprising: a head mounted device comprising at least one ultrasound transducer array, wherein the at least one ultrasound transducer array comprises ultrasound transducers positioned on opposite sides of a volume; and A controller, the controller being configured to: determining a first set of ultrasonic waves to be emitted by a first set of ultrasonic transducers in the at least one ultrasonic transducer array so as to achieve a desired ultrasonic stimulation energy at a target location within the volume, the target location corresponding to a target brain location, driving the first group of ultrasonic transducers according to the determined first group of ultrasonic waves, capturing free-field measurements of ultrasound waves using a second set of ultrasound transducers on an opposite side of the volume from the first set of ultrasound transducers when the head mounted device is not applied to the head, capturing through-transmission measurements of ultrasound waves using the second set of ultrasound transducers when the head mounted device is applied to the head, comparing the free field measurement and the through transmission measurement to determine attenuation and phase shift in the ultrasonic waves due at least in part to the presence of a skull in an ultrasonic path between the first set of ultrasonic transducers and the second set of ultrasonic transducers, determining an adjusted set of ultrasonic waves to be emitted by the first set of ultrasonic transducers, wherein the adjusted set of ultrasonic waves compensates for the determined attenuation and the determined phase shift to achieve the desired ultrasonic stimulation energy at the target location within the volume when the head mounted device is applied to the head; and The first set of ultrasonic transducers is driven according to the determined adjusted set of ultrasonic waves when the head mounted device is applied to the head.
9. The ultrasound delivery system of claim 8, wherein: The at least one ultrasound transducer array includes a plurality of ultrasound transducers, each ultrasound transducer being positioned and oriented to project an ultrasound beam along a different ultrasound path, wherein the controller is further configured to identify the first group of ultrasonic transducers by identifying ultrasonic transducers having ultrasonic paths that will intersect at the target location, and The controller is configured to determine the first group of ultrasonic waves to be emitted by the first group of ultrasonic transducers so as to achieve the expected ultrasonic stimulation energy at the target location by determining a combination of ultrasonic waves, wherein when the ultrasonic paths intersect at the target location, the ultrasonic waves will be combined by superposition to generate the expected ultrasonic stimulation energy.
10. The ultrasound delivery system of claim 8, wherein: The controller is also configured to determine the attenuation and the phase shift caused by the ultrasound wave passing through the skull once based in part on a difference between the measured ultrasound wave passing through the free field volume and the measured changed ultrasound wave passing through the head, wherein the difference indicates the attenuation and phase shift caused by the ultrasound wave passing through each segment of the head.
11. The ultrasound delivery system of claim 8, wherein: The controller is further configured to determine a plurality of skull attenuation values, the plurality of skull attenuation values comprising a determined skull attenuation value for each of the first set of ultrasound transducers, wherein each of the plurality of skull attenuation values indicates attenuation caused by the ultrasound wave emitted by the corresponding ultrasound transducer passing through the skull once, and Wherein, the controller is configured to determine the adjusted ultrasound group by scaling the amplitude of the ultrasound wave emitted by each ultrasound transducer in the first group of ultrasound transducers by a factor corresponding to the multiplicative inverse element of the determined skull attenuation value of the corresponding ultrasound transducer.
12. The ultrasound delivery system of claim 11, wherein: Determining the plurality of skull attenuation values includes calculating the skull attenuation value for each of the first set of ultrasound transducers according to: Among them, A ij is the attenuation of the ultrasound wave caused by the ultrasound wave passing through both sides of the skull, A i is the skull attenuation of the ultrasonic transducer caused by the first ultrasonic wave entering the head through the first side of the skull, A j is the attenuation of the ultrasound wave due to the ultrasound wave leaving the head through the second side of the skull, and k ij is the multiplicative inverse of the cosine of the relative angle of the ultrasonic beam emitted by the first ultrasonic transducer.
13. The ultrasound delivery system of claim 8, wherein: At least one arrayed ultrasound transducer includes a first ultrasound transducer array and a second ultrasound transducer array, wherein the head mounted device includes a frame coupling the first ultrasound transducer array and the second ultrasound transducer array to the head mounted device on opposite sides of the volume.
14. The ultrasound delivery system of claim 8, wherein: The head mounted device includes a crown-shaped body having a first opening and a second opening opposite to the first opening, wherein the first opening is sized to accommodate the head, and the top of the head remains exposed through the second opening when worn.
15. The ultrasound delivery system of claim 8, wherein: The head mounted device includes an adjustable support mechanism for positioning and supporting the head mounted device on the head when worn.
16. A method of applying ultrasound to a target brain location, the method comprising: driving the ultrasound transducer array to perform through-transmission ultrasound measurements through the head; determining, based on the through-transmission ultrasound measurements, attenuation values and phase shift values due at least in part to the presence of the head in an ultrasound path; determining an adjusted amplitude and phase value for each ultrasonic transducer of the ultrasonic transducer array based at least in part on the determined attenuation value and the determined phase shift value; as well as The ultrasound transducer array is driven based on the adjusted amplitude and phase values of each ultrasound transducer to achieve a desired ultrasound intensity at a target brain location within the head.
17. The method according to claim 16, wherein: The resulting ultrasound intensity inside the head provides effective ultrasound modulation of the activity of neurons and other excitable cells.
18. The method according to claim 16, wherein: The resulting ultrasound intensity inside the head provides effective activation of ultrasound-sensitive nanoparticle carriers to release neuromodulatory therapeutic agents from the carriers to the target brain location.
19. The method according to claim 18, wherein: The neuromodulatory therapeutic agent provides a clinically relevant dose to the target brain location.
20. The method according to claim 19, wherein: The neuromodulatory therapeutic agent is propofol encapsulated in the nanoparticle carrier at a concentration of 0.063 mg / ml.
21. The method according to claim 16, wherein: The resulting ultrasound intensity inside the head provides efficient activation of microbubbles to temporarily disrupt the blood-brain barrier for local delivery of drugs, genes and stem cells across the blood-brain barrier.
Citation Information
Cited By
Human body transcranial ultrasonic irradiation method and device, electronic equipment and storage medium
CN119185819A
Transcranial focused ultrasound stimulation system and method for cognitive impairment patient
CN119280719A
Device for sonodynamic treatment of brain glioma
CN119896532A
